|Description||Adomeglivant has been found to be a glucagon receptor antagonist that could probably be effective for both type-I and type-II diabetes mellitus.|
|Synonyms||Adomeglivant; LY-2409021; Adomeglivant [USAN]; UNII-74Z5ZL2KVG; LY2409021; LY 2409021; 3-[[4-[(1S)-1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]benzoyl]amino]propanoic acid|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
|Current Developer||Eli Lilly|
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist (EC50= 0.06 nM) under investigation for treatment of type 2 diabetes.
CP 316819 has been found to be a glycogen phosphorylase inhibitor and could probably be used in the treatment for glycemic control in type 2 diabetes.
glucagon receptor antagonists-2
glucagon receptor antagonists-2 is a highly potent antagonist of glucagon receptor .
Exenatide acetate is a potent peptide agonist of the glucagon-like peptide 1 (GLP-1) receptor with Ki value of 136 pM. It is a 39 amino acid peptide, which incr...
Adomeglivant has been found to be a glucagon receptor antagonist that could probably be effective for both type-I and type-II diabetes mellitus.
Exendin (9-39) is a specific and competitive glucagon-like peptide-1receptor antagonist (Kd = 1.7 nM at cloned human GLP-1 receptors). Exendin (9-39) inhibits i...
MK-0893 is a selective glucagon receptor antagonist. It can block glucagon binding to the human GCGR and antagonize glucagon-induced intracellular accumulation ...
GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model, with IC50 of 56 and 55 nM for rat and human gluca...